All‐cause mortality (5 days to 12 months) · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in all‐cause mortality (5 days to 12 months) compared with intravenous unfractionated heparin (low certainty).
1 finding from 1 review
Asymptomatic VTE at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptomatic recurrent VTE at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in symptomatic recurrent VTE at 3 months compared with low molecular weight heparin (low certainty).
1 finding from 1 review
Symptomatic recurrent DVT at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in symptomatic recurrent DVT at 3 months compared with low molecular weight heparin (low certainty).
1 finding from 1 review
Intervention not reported
Heparin‐induced thrombocytopenia (HIT) · people undergoing surgical procedures and treated with UFH or LMWH for prophylaxis of thrombotic events lasting at least 5 days
The intervention may leads to lower heparin‐induced thrombocytopenia (HIT) (low certainty).
1 finding from 1 review
Intervention not reported
HIT in people undergoing major surgical procedures · people undergoing surgical procedures and treated with UFH or LMWH for prophylaxis of thrombotic events lasting at least 5 days
The intervention may leads to lower HIT in people undergoing major surgical procedures (low certainty).
1 finding from 1 review
Intervention not reported
HIT complicated by venous thromboembolism · people undergoing surgical procedures and treated with UFH or LMWH for prophylaxis of thrombotic events lasting at least 5 days
The intervention may leads to lower HIT complicated by venous thromboembolism (low certainty).
1 finding from 1 review
All‐cause mortality, 30 days1 · patients of any age with AAA less than 30 mm in diameter
Metoprolol showed no clear difference in all‐cause mortality, 30 days1 compared with placebo (low certainty).
1 finding from 1 review
All cardiovascular death · patients of any age with AAA less than 30 mm in diameter
Metoprolol showed no clear difference in cardiovascular death, 30 days3 compared with placebo (low certainty).
2 findings from 1 review
AAA‐related death, 30 days4 · patients of any age with AAA less than 30 mm in diameter
Metoprolol showed no clear difference in AAA‐related death, 30 days4 compared with placebo (low certainty).
2 findings from 1 review
Nonfatal cardiovascular event, 30 days5 · patients of any age with AAA less than 30 mm in diameter
Metoprolol showed no clear difference in nonfatal cardiovascular event, 30 days5 compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality, 6 months1 · patients of any age with AAA less than 30 mm in diameter
Metoprolol showed no clear difference in all‐cause mortality, 6 months1 compared with placebo (low certainty).
1 finding from 1 review
Non‐fatal cardiovascular events · patients of any age with AAA less than 30 mm in diameter
Metoprolol showed no clear difference in nonfatal cardiovascular event, 6 months5 compared with placebo (low certainty).
1 finding from 1 review
VTE‐related mortality4 · patients with unprovoked venous thromboembolism
Extended prophylaxis showed no clear difference in VTE‐related mortalitya compared with placebo (low certainty).
1 finding from 1 review
Major bleeding · patients with unprovoked venous thromboembolism
VTE extended prophylaxis showed no clear difference in major bleedingd compared with another VTE extended prophylaxis (moderate certainty).
1 finding from 1 review
All‐cause mortalitye · patients with unprovoked venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · patients with unprovoked venous thromboembolism
VTE extended prophylaxis showed no clear difference in clinically relevant non‐major bleedingf compared with another VTE extended prophylaxis (moderate certainty).
1 finding from 1 review
Strokeg · patients with unprovoked venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Myocardial infarction · patients with unprovoked venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent VTEc · patients with unprovoked venous thromboembolism
Extended prophylaxis showed no clear difference in recurrent VTEc compared with placebo (moderate certainty).
1 finding from 1 review